Skip to content
HowShorted

EAGLE PHARMACEUTICALS, INC. short interest in 2018

In 2018, EAGLE PHARMACEUTICALS, INC.'s disclosed short interest ran from 21.16% of shares outstanding on 12 Jan 2018 to 18.97% on 31 Dec 2018, a change of -2.19 percentage points. The year's high was 22.36% on 15 Mar 2018 and its low 16.15% on 13 Jul 2018, averaging 18.68% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.01 days on 30 Apr 2018. Full history: EAGLE PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for EAGLE PHARMACEUTICALS, INC. in 2018

2018 in figures

Start of year
21.16% (12 Jan 2018)
End of year
18.97% (31 Dec 2018)
Change
-2.19 pp
High
22.36% (15 Mar 2018)
Low
16.15% (13 Jul 2018)
Average
18.68%
Highest days to cover
18.01 (30 Apr 2018)
SEC filings marked
9

Every report in 2018

EAGLE PHARMACEUTICALS, INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201821.16%14.75
31 Jan 201820.18%14.57
15 Feb 201820.74%14.22
28 Feb 201822.34%7.3010-K filed, results (8-K)
15 Mar 201822.36%13.96
29 Mar 201821.37%15.01
13 Apr 201820.34%15.51
30 Apr 201819.31%18.01
15 May 201817.93%9.1410-Q filed, results (8-K)
31 May 201816.39%10.31
15 Jun 201817.48%8.67
29 Jun 201817.19%10.33
13 Jul 201816.15%12.10
31 Jul 201816.18%11.12
15 Aug 201817.19%10.3810-Q filed, results (8-K)
31 Aug 201817.12%11.93
14 Sep 201816.44%13.38
28 Sep 201817.62%9.79
15 Oct 201817.55%13.63
31 Oct 201818.94%7.69results (8-K)
15 Nov 201819.24%9.1210-Q filed, results (8-K)
30 Nov 201817.88%12.44
14 Dec 201818.16%10.09
31 Dec 201818.97%13.86

See also: EAGLE PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.